Eukles Asset Management Sells 303 Shares of Illumina, Inc. (NASDAQ:ILMN)

Eukles Asset Management decreased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 4.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,876 shares of the life sciences company’s stock after selling 303 shares during the quarter. Eukles Asset Management’s holdings in Illumina were worth $785,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Empowered Funds LLC grew its position in shares of Illumina by 1.7% during the 3rd quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company’s stock worth $516,000 after buying an additional 66 shares in the last quarter. Caprock Group LLC grew its stake in Illumina by 3.0% in the third quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company’s stock valued at $376,000 after purchasing an additional 83 shares during the last quarter. Integrated Advisors Network LLC raised its holdings in Illumina by 2.0% in the third quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company’s stock worth $585,000 after purchasing an additional 90 shares in the last quarter. Stephens Inc. AR lifted its position in shares of Illumina by 1.4% during the fourth quarter. Stephens Inc. AR now owns 6,623 shares of the life sciences company’s stock valued at $885,000 after buying an additional 90 shares during the last quarter. Finally, Moors & Cabot Inc. boosted its holdings in shares of Illumina by 1.7% in the 3rd quarter. Moors & Cabot Inc. now owns 5,818 shares of the life sciences company’s stock valued at $759,000 after buying an additional 95 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ILMN. JPMorgan Chase & Co. boosted their price objective on shares of Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Leerink Partners upped their price target on Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Piper Sandler lowered their price objective on Illumina from $195.00 to $185.00 and set an “overweight” rating for the company in a research report on Monday, November 11th. Barclays downgraded Illumina from an “equal weight” rating to an “underweight” rating and lowered their price target for the stock from $130.00 to $100.00 in a report on Monday. Finally, UBS Group lifted their target price on shares of Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $159.90.

Illumina Trading Down 9.6 %

Shares of Illumina stock opened at $111.06 on Monday. The stock has a market cap of $17.61 billion, a PE ratio of -14.46 and a beta of 1.10. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The firm has a fifty day moving average price of $136.70 and a 200 day moving average price of $135.43. Illumina, Inc. has a 1 year low of $100.08 and a 1 year high of $156.66.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 12.59%. Equities research analysts predict that Illumina, Inc. will post 4.42 earnings per share for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.